US.ABBV · AbbVie

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.2966476404855696,
        "turnoverUsdM": 1278.8137852,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.ABBV",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 237.3528,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 4.6,
      "take_profit_price": 263.0735,
      "target_multiplier": 1.9,
      "technical_strength": 1.98,
      "take_profit_percent": 5.7
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.240939162699524,
    "stopLossPercent": 4.593295280971139,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 57.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 257.578,
    "ma50": 254.387,
    "close": 248.78,
    "prevClose": 256.46,
    "avgVolume20": 4320592,
    "volumeRatio": 1.19,
    "changePercent": -2.99
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": -0.0297949056315846,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 1.202685977000737,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 1.3068418580689833,
      "volat_points": 2,
      "day_range_pct": 0.0249015596109013,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 57.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 18.1,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 60.33,
        "contribution": 18.1
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 50.4,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 18.1/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 6.8,
      "市場環境": 9.6,
      "情緒分析": 4,
      "技術信號": 18.1,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.3,
          "marginPoints": 0,
          "turnoverUsdM": 1278.8137852,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.ABBV",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.3
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.3850005500001,
                "ma50": 711.3217994399997,
                "name": "QQQ",
                "close": 718.35999,
                "points": 2
              },
              "spy": {
                "ma20": 768.6994929500001,
                "ma50": 757.5966012200001,
                "name": "SPY",
                "close": 765.96002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.2966476404855696,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141955092,
                "url": "https://finnhub.io/api/news?id=a3570a8f51e702b4ad365ed1e54378b3ca13602196c086498d198c6196c72445",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788903906,
                "headline": "AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 141437249,
                "url": "https://finnhub.io/api/news?id=f54514b5a264baa0511cd8c86ff191f75db1b2c6e2222a1bd86d330c9040a81a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.",
                "category": "company",
                "datetime": 1788533280,
                "headline": "ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study"
              },
              {
                "id": 141425445,
                "url": "https://finnhub.io/api/news?id=c4cc4ad5bbbae181b1ac0ac2626f7db1cd57e243dfbebe72fbb2b19d91ec1b6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...",
                "category": "company",
                "datetime": 1788513572,
                "headline": "AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma"
              },
              {
                "id": 141406890,
                "url": "https://finnhub.io/api/news?id=ea03395d0d2c06f797d9eca00c27a426428fc47906942b333329c65c46e30fcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]",
                "category": "company",
                "datetime": 1788485074,
                "headline": "AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400349,
                "url": "https://finnhub.io/api/news?id=d83525d9568d496cf432be05e0bc3130c4d26f569d0d1889194d2d2637e7a386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.",
                "category": "company",
                "datetime": 1788447720,
                "headline": "ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?"
              },
              {
                "id": 141360933,
                "url": "https://finnhub.io/api/news?id=be9d28b90aa9d6e22f6ff6fa4ab5a08d95fa0029eaa0c04a6ab9fe0bfc89241e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...",
                "category": "company",
                "datetime": 1788055670,
                "headline": "Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?"
              },
              {
                "id": 141278176,
                "url": "https://finnhub.io/api/news?id=60c1d685b6f9f61242d6bb6b2e8b7cb7a7bd12cfd211b1e9ef20c29498fd2d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...",
                "category": "company",
                "datetime": 1787332273,
                "headline": "AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026"
              }
            ],
            "raw_source": [
              {
                "id": 141955092,
                "url": "https://finnhub.io/api/news?id=a3570a8f51e702b4ad365ed1e54378b3ca13602196c086498d198c6196c72445",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788903906,
                "headline": "AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141952507,
                "url": "https://finnhub.io/api/news?id=5bc48b8fcb4082ca3a778081490904fe5568769496d5f9bf7ced0e48723eb43c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.",
                "category": "company",
                "datetime": 1788887100,
                "headline": "Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141951906,
                "url": "https://finnhub.io/api/news?id=8516a4e5e27068b7c69780eccea33f98d398d6703fa4e598ec89e1e4baf85c7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.",
                "category": "company",
                "datetime": 1788866855,
                "headline": "Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back"
              },
              {
                "id": 141872504,
                "url": "https://finnhub.io/api/news?id=0655996c0406ab8cda6df5322118e19cba39a60b11f929989d6ffbd0536a00a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid",
                "category": "company",
                "datetime": 1788854880,
                "headline": "Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca"
              },
              {
                "id": 141762536,
                "url": "https://finnhub.io/api/news?id=755171ce4130cab475d6d9e4eb412f6569c568e60203dffab6ff579c86acade5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.",
                "category": "company",
                "datetime": 1788699000,
                "headline": "Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It"
              },
              {
                "id": 141593651,
                "url": "https://finnhub.io/api/news?id=abd79ed984393837f1a616b04e48ecd336119888b355837cc8bf0f0db138fed0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.",
                "category": "company",
                "datetime": 1788615000,
                "headline": "Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze."
              },
              {
                "id": 141508595,
                "url": "https://finnhub.io/api/news?id=6561cc44b7d9bb5839f2817370437f5253b0801c189ff57d2948b6a12ddff07c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Owning these dividend stocks could be a simple way to make money over the long term.",
                "category": "company",
                "datetime": 1788599040,
                "headline": "3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)"
              },
              {
                "id": 141472672,
                "url": "https://finnhub.io/api/news?id=b05569a2726dbfca222fbb49233a94c889b7b980720e4a5982da2add37873521",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...",
                "category": "company",
                "datetime": 1788563646,
                "headline": "ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board"
              },
              {
                "id": 141455037,
                "url": "https://finnhub.io/api/news?id=882e78db4092ee8e4a4f8c9153c570608198427b13f54f3413147816ac706bb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.",
                "category": "company",
                "datetime": 1788547801,
                "headline": "AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141437224,
                "url": "https://finnhub.io/api/news?id=38778bfaa72d5114c393b0f60959573175899d0ce0932c17d1256f7858796355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535831,
                "headline": "Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?"
              },
              {
                "id": 141431565,
                "url": "https://finnhub.io/api/news?id=152f3cfaab33672e18cec638932d7543735e5fc8e8ba605a7a688651df42f09d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.",
                "category": "company",
                "datetime": 1788533950,
                "headline": "AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?"
              },
              {
                "id": 141437249,
                "url": "https://finnhub.io/api/news?id=f54514b5a264baa0511cd8c86ff191f75db1b2c6e2222a1bd86d330c9040a81a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.",
                "category": "company",
                "datetime": 1788533280,
                "headline": "ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study"
              },
              {
                "id": 141431506,
                "url": "https://finnhub.io/api/news?id=95214a8af28f2cbdda35ff4812d8d6ba21b0a0f61a6f69305895fbbbdecb5d4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.",
                "category": "company",
                "datetime": 1788532140,
                "headline": "The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge"
              },
              {
                "id": 141425444,
                "url": "https://finnhub.io/api/news?id=3821c9f8ed47a4fde022991516a120bc6b93514a623a4318dc7d799040d2c6b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.",
                "category": "company",
                "datetime": 1788526836,
                "headline": "Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely"
              },
              {
                "id": 141446631,
                "url": "https://finnhub.io/api/news?id=acc97bf164cbb510d5f95d4dd90bb12e4789e33a92896040efbc52ce5956ac8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.",
                "category": "company",
                "datetime": 1788523200,
                "headline": "Trailing rivals, AbbVie scores win with dual-acting myeloma drug"
              },
              {
                "id": 141446625,
                "url": "https://finnhub.io/api/news?id=c3f0ce25405e3a4a658c9e06cd609f8c5238342b85a42c14dd02819bf7143560",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.",
                "category": "company",
                "datetime": 1788522991,
                "headline": "This week in charts: China deals, stock flatlines and Lilly’s M&A spree"
              },
              {
                "id": 141425445,
                "url": "https://finnhub.io/api/news?id=c4cc4ad5bbbae181b1ac0ac2626f7db1cd57e243dfbebe72fbb2b19d91ec1b6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...",
                "category": "company",
                "datetime": 1788513572,
                "headline": "AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma"
              },
              {
                "id": 141408334,
                "url": "https://finnhub.io/api/news?id=13e200695c1aeee0973bb2bb1f6d4cb039b9dac501882f2c7c66b7654de92901",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.",
                "category": "company",
                "datetime": 1788491273,
                "headline": "AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)"
              },
              {
                "id": 141406890,
                "url": "https://finnhub.io/api/news?id=ea03395d0d2c06f797d9eca00c27a426428fc47906942b333329c65c46e30fcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]",
                "category": "company",
                "datetime": 1788485074,
                "headline": "AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story"
              },
              {
                "id": 141405266,
                "url": "https://finnhub.io/api/news?id=c6bd33d02f29c0e746284189acdf6115b5d12911d72d569813035109ff4bef15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Why Short Sellers Are Running Scared from These Stocks",
                "category": "company",
                "datetime": 1788470372,
                "headline": "The \"Untouchable\" List: Stocks That Short Sellers Won't Dare Bet Against"
              },
              {
                "id": 141403889,
                "url": "https://finnhub.io/api/news?id=b0804b234e511e69808b38f92c6ee8ffc81d307ea5abe364d75d67f8e8966f56",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.",
                "category": "company",
                "datetime": 1788468720,
                "headline": "Top Analyst Reports for Amazon, AbbVie & Alibaba"
              },
              {
                "id": 141403793,
                "url": "https://finnhub.io/api/news?id=b21fbc8bc432a588b3cef8a19be98c69f35350ce69bb543e32f8195888b9d421",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre",
                "category": "company",
                "datetime": 1788464762,
                "headline": "Sector Update: Healthcare Stocks Edge Higher Late Afternoon"
              },
              {
                "id": 141403795,
                "url": "https://finnhub.io/api/news?id=1b41c961a3f0db6d6337553b4263e9af3679f29fcbaff8c55324683f0ef70771",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The study demonstrated that the drug outperformed standard therapies, meeting its primary goals for objective response rate and progression-free survival. Read Also: Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report Efficacy And Trial Metrics At a median follow-up of 11.4 months, resear",
                "category": "company",
                "datetime": 1788459023,
                "headline": "AbbVie Touts Positive Data For Multiple Myeloma Drug"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400360,
                "url": "https://finnhub.io/api/news?id=1d4d3880694c9b85844e53ef2e9fdcc233f5c7a2de000b7984566a92a2fc0394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449421,
                "headline": "Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400349,
                "url": "https://finnhub.io/api/news?id=d83525d9568d496cf432be05e0bc3130c4d26f569d0d1889194d2d2637e7a386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.",
                "category": "company",
                "datetime": 1788447720,
                "headline": "ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?"
              },
              {
                "id": 141400348,
                "url": "https://finnhub.io/api/news?id=c713b71330fa32d06e3d764e47076891791db9e7f2eaf72967dd5569d778a719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years.",
                "category": "company",
                "datetime": 1788446465,
                "headline": "AbbVie could take BiTE of Tecvayli market share on Phase III MM win"
              },
              {
                "id": 141398023,
                "url": "https://finnhub.io/api/news?id=7f0e2193e6aaa1cee1355a49e4681cca2b0d7a96f42f8eb351ee86ece38be1de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.",
                "category": "company",
                "datetime": 1788442440,
                "headline": "AbbVie Completes Acquisition of Apogee Therapeutics"
              },
              {
                "id": 141399146,
                "url": "https://finnhub.io/api/news?id=0349daf45e6213305e3eb7f8e5e6c624f2342b134c257d956c55ac129b7f2d46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM). The study met its dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS). Full results will",
                "category": "company",
                "datetime": 1788441300,
                "headline": "AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma"
              },
              {
                "id": 141397950,
                "url": "https://finnhub.io/api/news?id=ca14c9b66e15a6c38f449511256119e6886f26476548d7c9a4a8dad80c9c368c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time.",
                "category": "company",
                "datetime": 1788440700,
                "headline": "AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141399764,
                "url": "https://finnhub.io/api/news?id=1edff4a8045874e4f4d1503cf34452cb3fdd9656b69d2f10505a246618b148b9",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) affirms FY2026 Adj EPS guidance from $13.87-$14.07 to $13.87-$14.07 vs $14.08 analyst estimate..",
                "category": "company",
                "datetime": 1788427068,
                "headline": "AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 Est"
              },
              {
                "id": 141399765,
                "url": "https://finnhub.io/api/news?id=f72682177fdd8b558fb58a27f7a7568a44827ff3c6ba3c6e05bf663b2ea1a6f2",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) affirms Q3 Adj EPS guidance from $3.84-$3.88 to $3.84-$3.88 vs $3.84 analyst estimate..",
                "category": "company",
                "datetime": 1788427062,
                "headline": "AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 Est"
              },
              {
                "id": 141399766,
                "url": "https://finnhub.io/api/news?id=c9e47322748ac27479889093a5ef76fdcdb9f2b194f5a8337c7b3ae479a83f7a",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus",
                "category": "company",
                "datetime": 1788427009,
                "headline": "Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26"
              },
              {
                "id": 141399767,
                "url": "https://finnhub.io/api/news?id=44e4369d56ac92a8e49151a95932410a5641868b31771e26c65b38b92dd97cb9",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion",
                "category": "company",
                "datetime": 1788425177,
                "headline": "AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379561,
                "url": "https://finnhub.io/api/news?id=32a3bfaca91f3c2965791c99b25dca43c62d6af35d2e71468a23e4c493ec39e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Most retirees assume hitting a $68,400 annual income floor demands either a massive nest egg or risky high-yield instruments, but five ordinary dividend stocks across five sectors challenge both assumptions in ways the math makes hard to ignore.",
                "category": "company",
                "datetime": 1788365126,
                "headline": "No ETFs Required: How a 64-Year-Old Built a $5,700 Monthly Paycheck From Five Dividend Stocks"
              },
              {
                "id": 141379563,
                "url": "https://finnhub.io/api/news?id=2870c203a702b36bc9de60583eec320e814949a354fd9c25262b9eb825cb345a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Kymera Therapeutics' (KYMR) KT-621 could validate its \"oral Dupixent\" potential, but with a roughly",
                "category": "company",
                "datetime": 1788364753,
                "headline": "Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              },
              {
                "id": 141376411,
                "url": "https://finnhub.io/api/news?id=4e6c6dfe7e76bb73b6140437f2501284597f3339e4a531d3bbeaab4d49786d73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, today unveiled the Layered Beauty: The New Aesthetic Mindset report, informed by research among more than 12,000 beauty-involved consumers across nine global markets, complemented by practitioner expertise and regional perspectives. The report provides a global perspective on the impact of cultural attitudes toward beauty and aging to evolve the aesthetic treatment landscape and offers healthcare providers new perspectives on the behaviors shaping today's",
                "category": "company",
                "datetime": 1788354000,
                "headline": "Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care"
              },
              {
                "id": 141377997,
                "url": "https://finnhub.io/api/news?id=7b8758e202d8fe4bd88cfec11ba4a82a644d1cfb2b78e14289edbb9e15347d28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161979533/image_2161979533.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Clinuvel Pharmaceuticals Limited analysis: SCENESSE profits, A$252M cash/no debt, and CUV105 vitiligo trial catalyst vs AbbVie/Pfizer risks—click for more on CUVL.",
                "category": "company",
                "datetime": 1788347567,
                "headline": "5 Reasons To Buy Clinuvel Pharmaceuticals After Its Nasdaq Uplisting"
              },
              {
                "id": 141375563,
                "url": "https://finnhub.io/api/news?id=7ab5bcd12588ce30f4b5b5a311969bf31606f4bc2cce08218a7a22084c60a831",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Johnson & Johnson's valuation is above historical averages, already pricing in competent execution. Find out why JNJ stock is a hold.",
                "category": "company",
                "datetime": 1788334184,
                "headline": "Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half"
              },
              {
                "id": 141369838,
                "url": "https://finnhub.io/api/news?id=f54682b0be71e2c22431932fafa4cec47274c5af0413a26f923d05835763f1d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalizatio",
                "category": "company",
                "datetime": 1788280620,
                "headline": "A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture"
              },
              {
                "id": 141360827,
                "url": "https://finnhub.io/api/news?id=59f156868ac7b9423ef388b02aa29bf66e03e13e0c5da7f989326c379febef36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.",
                "category": "company",
                "datetime": 1788273780,
                "headline": "GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?"
              },
              {
                "id": 141360939,
                "url": "https://finnhub.io/api/news?id=eb7c441f4924679ac51ceec57c7fbbe0342ae29b037b247607693a7299bef776",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.",
                "category": "company",
                "datetime": 1788267900,
                "headline": "SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings"
              },
              {
                "id": 141360820,
                "url": "https://finnhub.io/api/news?id=1df0df20de7aabb85df09fc4c34c5731bfc6fe40781bd266d3afd73797d03fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.",
                "category": "company",
                "datetime": 1788202928,
                "headline": "This Popular Healthcare ETF Is Diluting Your Dividend Income"
              },
              {
                "id": 141360940,
                "url": "https://finnhub.io/api/news?id=036a665dfcf2073c36a6a6f575341e937f13f43edd6e086929670ab6bb25ecb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.",
                "category": "company",
                "datetime": 1788193740,
                "headline": "Aging Population Drives Healthcare Growth: Stocks to Watch"
              },
              {
                "id": 141360941,
                "url": "https://finnhub.io/api/news?id=93daf068001f0177a626163885017d0747b3e30922e44b72d9ae6fc4a49d8e10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "BRONX, N.Y., August 31, 2026--Cassino appointed Interim President and CEO of Oligomerix",
                "category": "company",
                "datetime": 1788189000,
                "headline": "Oligomerix Appoints Biopharmaceutical Industry Veteran Cara Cassino, M.D. as Interim President and Chief Executive Officer"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141360942,
                "url": "https://finnhub.io/api/news?id=a00ec139b3825f2322a7be73e8c4eb036057b7fa5ebffd92ed83f57b283f2b07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) will participate in the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. Management will participate in a fireside chat at 9:15 a.m. Central time.",
                "category": "company",
                "datetime": 1788181200,
                "headline": "AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141360873,
                "url": "https://finnhub.io/api/news?id=6b7828153da95e7d98471f4497d58e848236a54aadd439f193674200df7e7991",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The global palmoplantar pustulosis market is expanding as awareness, diagnosis rates and demand for targeted biologic therapies increase. Advances in IL-23 and IL-36 research, precision medicine, biomarker discovery and AI-assisted diagnostics are accelerating treatment development. Topical therapies remain central to mild cases, while systemic agents and biologics support moderate-to-severe disease management. Growth across North America, Europe and Asia-Pacific is reinforced by clinical trials",
                "category": "company",
                "datetime": 1788170580,
                "headline": "Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel"
              },
              {
                "id": 141360932,
                "url": "https://finnhub.io/api/news?id=cc114ac264e5e7ac999fb16cce8202aaf2dc37710e888db65f20fd1ed2184ea9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.",
                "category": "company",
                "datetime": 1788121264,
                "headline": "How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks"
              },
              {
                "id": 141360933,
                "url": "https://finnhub.io/api/news?id=be9d28b90aa9d6e22f6ff6fa4ab5a08d95fa0029eaa0c04a6ab9fe0bfc89241e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "What AbbVie’s Skyrizi EMA filing means for ABBV stock AbbVie (ABBV) has moved to expand Skyrizi’s role in Crohn's disease treatment by submitting an application to the European Medicines Agency for a subcutaneous induction regimen in adults with moderately to severely active disease. The filing, backed by Phase 3 AFFIRM data, comes as AbbVie stock reflects a mixed recent pattern, with the share price down over the past week but higher over the past month, past 3 months and past year. At a...",
                "category": "company",
                "datetime": 1788055670,
                "headline": "Is AbbVie (ABBV) Undervalued As It Expands Skyrizi In Crohns Disease?"
              },
              {
                "id": 141360934,
                "url": "https://finnhub.io/api/news?id=e75b3343068a20ea2025e983f8bae1f6fc7738b3a35bd3721350805f8408dc05",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.",
                "category": "company",
                "datetime": 1788035701,
                "headline": "AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141348564,
                "url": "https://finnhub.io/api/news?id=7009d4f82a8712cebfa86427db9a724d72e0b2b5febcd81764d5d26f56545d3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.",
                "category": "company",
                "datetime": 1788028861,
                "headline": "AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141348569,
                "url": "https://finnhub.io/api/news?id=5caec48fa8c298b9b7ae22abf3e8a0748a26e4cee3ef928bc307c833666febd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The signs were not in the headline growth rate but in which two products were trading places.",
                "category": "company",
                "datetime": 1787947785,
                "headline": "Did A Product Swap Fuel JNJ Stock’s 54% Surge?"
              },
              {
                "id": 141348570,
                "url": "https://finnhub.io/api/news?id=4f0e161ba9b9cba902841c73156b0682cae4aa772893993f336979cf573e608d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.",
                "category": "company",
                "datetime": 1787945738,
                "headline": "Can Merck Stock Outrun Its Pipeline?"
              },
              {
                "id": 141348574,
                "url": "https://finnhub.io/api/news?id=bccdb8949eb8455112a628da229c67281716d6b62b4b8301c175c0c98232cce2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.",
                "category": "company",
                "datetime": 1787932380,
                "headline": "AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease"
              },
              {
                "id": 141336158,
                "url": "https://finnhub.io/api/news?id=273f7d95e1c5d87e6583c19ca260c46b48b3faba6504ba6427a6d5bbc614e7b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1787870965,
                "headline": "Slate Medicines Starts Migraine Treatment Study"
              },
              {
                "id": 141360948,
                "url": "https://finnhub.io/api/news?id=d996d90295ae96f1cb973a3c6604fa866b3ac5806908170eba6410dd94f3ffe8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.",
                "category": "company",
                "datetime": 1787853707,
                "headline": "Is Merck Stock Reaching A Valuation Ceiling At 6x Sales?"
              },
              {
                "id": 141360937,
                "url": "https://finnhub.io/api/news?id=84f51015e523d64d52ac7317d9d5d041b156c25ea44dc372d3716dee359a4f51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Three blue-chip dividend stocks, each on a different quarterly payment schedule, can fill every month of the year with income, but each one carries a distinct risk that could derail the whole ladder.",
                "category": "company",
                "datetime": 1787849525,
                "headline": "3 Rock Solid Dividend That Pay You Every Month"
              },
              {
                "id": 141360949,
                "url": "https://finnhub.io/api/news?id=db3938b666fed616eb0e253bbc6d4bf903231e7634103b3b89e617a8cca475b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.",
                "category": "company",
                "datetime": 1787844540,
                "headline": "FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now"
              },
              {
                "id": 141332834,
                "url": "https://finnhub.io/api/news?id=c2b32142c6859d6242411254cd9c0d1b190eccbbed3fd9a816d9ec606f223589",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)",
                "category": "company",
                "datetime": 1787797522,
                "headline": "AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data"
              },
              {
                "id": 141332835,
                "url": "https://finnhub.io/api/news?id=eaf31b5fe024344177d00a52a52472851615ce754b223d57df58e3340dd8bbd8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.",
                "category": "company",
                "datetime": 1787760044,
                "headline": "If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141322438,
                "url": "https://finnhub.io/api/news?id=5b89a111c396ce77d686a5f752a6b55a41ab4baa4c092d77332afe86e3a63eb8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.",
                "category": "company",
                "datetime": 1787731357,
                "headline": "TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)"
              },
              {
                "id": 141310616,
                "url": "https://finnhub.io/api/news?id=38df87f131886e4d349efc9b4be1ba0f200d1422d4c79a683e56e4e4c5f7d908",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "AbbVie stock outlook: Skyrizi & Rinvoq fuel EPS growth as Humira declines. Forward P/E and PEG suggest undervaluation.",
                "category": "company",
                "datetime": 1787585511,
                "headline": "AbbVie Still Has Room To Run"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141300693,
                "url": "https://finnhub.io/api/news?id=b2d3954f42ad4308cb6ececb4c1f27e3744121249232ae5fd9158ac623138f63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445033385/image_1445033385.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Nvidia earnings, core PCE inflation and Warsh’s Jackson Hole debut could move markets.",
                "category": "company",
                "datetime": 1787469186,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278176,
                "url": "https://finnhub.io/api/news?id=60c1d685b6f9f61242d6bb6b2e8b7cb7a7bd12cfd211b1e9ef20c29498fd2d3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...",
                "category": "company",
                "datetime": 1787332273,
                "headline": "AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026"
              },
              {
                "id": 141278177,
                "url": "https://finnhub.io/api/news?id=d3e097a5d8c15fd8c5176dca5c1ad75b2bd1ca513727d8d1be6ca306e501211f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker ident",
                "category": "company",
                "datetime": 1787316300,
                "headline": "AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline"
              },
              {
                "id": 141278181,
                "url": "https://finnhub.io/api/news?id=5313d91c3b843c6f3a057b8170dbd154d190a706415bf1a358d2947c51990ca0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
                "category": "company",
                "datetime": 1787315987,
                "headline": "3 Unpopular Stocks That Deserve Some Love"
              },
              {
                "id": 141272430,
                "url": "https://finnhub.io/api/news?id=c1c8f433c9e3ecc1be8382ae26b6e9f63d8875fd36d4f809ebf51ef75033bf82",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer",
                "category": "company",
                "datetime": 1787298429,
                "headline": "AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141278178,
                "url": "https://finnhub.io/api/news?id=825fce49981a44b34b1fcec43c28562d1e561a59a0a7eb4ae5530e27f611253d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind each target may surprise you.",
                "category": "company",
                "datetime": 1787247035,
                "headline": "Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead"
              },
              {
                "id": 141278184,
                "url": "https://finnhub.io/api/news?id=3ea1d143456f4c7d9dc7cd996cce3a54cc68abe50ff8abf5c998e7b1c4fae3f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.",
                "category": "company",
                "datetime": 1787244840,
                "headline": "GKOS Stock Surges 67% Year to Date: What's Driving the Rally?"
              },
              {
                "id": 141278185,
                "url": "https://finnhub.io/api/news?id=b6f5547aae60787470f795a553206b912e475489277993b14623fbbb126e01ff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.",
                "category": "company",
                "datetime": 1787240880,
                "headline": "Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?"
              },
              {
                "id": 141278139,
                "url": "https://finnhub.io/api/news?id=fcd332a3e0e30fe8a0f7d63cb0a926be225e4bb853171cc00071bc6cf71d34d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.",
                "category": "company",
                "datetime": 1787240431,
                "headline": "Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO"
              },
              {
                "id": 141265376,
                "url": "https://finnhub.io/api/news?id=a1b2cbf52cdcac69f367a4c5d8d777f76a215fe0fbbd1c88e4f1ed7fe19ee1df",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Piper Sandler  analyst David Amsellem   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.",
                "category": "company",
                "datetime": 1787228114,
                "headline": "Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141265019,
                "url": "https://finnhub.io/api/news?id=3efe1267e5f6f11310f69d408807179b90b236964e8bbc86180a9ae298656234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.",
                "category": "company",
                "datetime": 1787173696,
                "headline": "Johnson & Johnson Stock Runs On A Calendar The Market Does Not Set"
              },
              {
                "id": 141278141,
                "url": "https://finnhub.io/api/news?id=f9a21b5be4efd6c3499dc4de20ff1853c616d3d46fa5e2c4daf0a6b0846d3792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.",
                "category": "company",
                "datetime": 1787172052,
                "headline": "Is AbbVie Stock About To Break Out Again?"
              },
              {
                "id": 141278190,
                "url": "https://finnhub.io/api/news?id=bd31c4f774a8001880ac335a7929b8583da52983043d51e50f7a2be5384202a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1787160756,
                "headline": "Real Parkinson’s Disease Hope from Jupiter Neurosciences"
              },
              {
                "id": 141254920,
                "url": "https://finnhub.io/api/news?id=e89c64709ddd6a7995aae1754791a3f6d88481af9be88c0efb732c183203d1e2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1787148432,
                "headline": "Novo Nordisk: The Best Value In Pharma"
              },
              {
                "id": 141278191,
                "url": "https://finnhub.io/api/news?id=0e45fb5918e6aef86d7c7007e1515e398894910359d485907644078f3193217c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.",
                "category": "company",
                "datetime": 1787141400,
                "headline": "Billionaire Ken Griffin Increased His Position in This Dividend King by 547%"
              },
              {
                "id": 141278192,
                "url": "https://finnhub.io/api/news?id=c16a4fc0b4883ced1e09a9b7c881e88177284270c9e703188f98c2fc2d2d929d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.",
                "category": "company",
                "datetime": 1787065823,
                "headline": "Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore"
              },
              {
                "id": 141247734,
                "url": "https://finnhub.io/api/news?id=a607edaa23bb540143fdfe73de9dde5d38de54822e9469632d272690e461761a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787060120,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141278179,
                "url": "https://finnhub.io/api/news?id=79931f6c8ec57b8d7f52a4111b348cb66324ff1c625802c0b5acc4d064f003a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10th year.",
                "category": "company",
                "datetime": 1787058000,
                "headline": "AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141238857,
                "url": "https://finnhub.io/api/news?id=292ccba92e495cfc2bc773b240ec1429bff79de77dddc692c061eca0a3ebad65",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $295 to $300.",
                "category": "company",
                "datetime": 1786957469,
                "headline": "Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300"
              },
              {
                "id": 141216587,
                "url": "https://finnhub.io/api/news?id=e0bfe2d8f1befab153ba143c71be4362c346fc315cdcd21e2c0c3bf657df1d57",
                "image": "",
                "source": "Fintel",
                "related": "ABBV",
                "summary": "",
                "category": "company",
                "datetime": 1786717602,
                "headline": "Wolfe Research Upgrades AbbVie (ABBV)"
              },
              {
                "id": 141212149,
                "url": "https://finnhub.io/api/news?id=06ce5ec61bf64aaa7c2229ee32f5c18ed46a26b1f616e9dbdf69a8cc211b50fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]",
                "category": "company",
                "datetime": 1786664315,
                "headline": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?"
              },
              {
                "id": 141212141,
                "url": "https://finnhub.io/api/news?id=b37de892ed668dadc063cca94c87fdf98a4674d68db4572b055b93442e76bb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]",
                "category": "company",
                "datetime": 1786662446,
                "headline": "Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?"
              },
              {
                "id": 141210872,
                "url": "https://finnhub.io/api/news?id=0dbf6b24d123f0a154351a53eec26a89c1aa6fe99f4dd3171433292f42b33bbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D […]",
                "category": "company",
                "datetime": 1786656786,
                "headline": "Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141206518,
                "url": "https://finnhub.io/api/news?id=9069d19d991acf04b9fca1c8a243ae50a474fe8d50a62762c1f60f1f800987d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.",
                "category": "company",
                "datetime": 1786629121,
                "headline": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation"
              },
              {
                "id": 141209899,
                "url": "https://finnhub.io/api/news?id=d1a76c860af5738244eaf199d5b7aadc2e317507eca44c358c8ce07d3a785a86",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.",
                "category": "company",
                "datetime": 1786626886,
                "headline": "Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target"
              },
              {
                "id": 141204884,
                "url": "https://finnhub.io/api/news?id=2f7edaf5d4d41b70d1c840109cb90b6618fd34f237bd841243f92642f438c4d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.",
                "category": "company",
                "datetime": 1786622027,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More"
              },
              {
                "id": 141203838,
                "url": "https://finnhub.io/api/news?id=b33f48fc75f1b9ffcfdf982f5269f978b42b2ad1137e5f452919966d0bda6944",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249791973/image_2249791973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "ABBV",
                "summary": "Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.",
                "category": "company",
                "datetime": 1786596000,
                "headline": "American Century Focused Global Growth Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200513,
                "url": "https://finnhub.io/api/news?id=c73a8f0475758d31cd448380b74cbbb1c57e712f593a1a9679b90a05f53a54ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.",
                "category": "company",
                "datetime": 1786559422,
                "headline": "Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield"
              },
              {
                "id": 141200500,
                "url": "https://finnhub.io/api/news?id=ff75988727fcba1e5d818840746487c01f069e154db33e9b2aabc87f756101ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.",
                "category": "company",
                "datetime": 1786551148,
                "headline": "The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141200618,
                "url": "https://finnhub.io/api/news?id=13f1298ebc4c518c0dd79feda3636de8fb9afa9966b4932b224c23998ef49532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...",
                "category": "company",
                "datetime": 1786486514,
                "headline": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141200620,
                "url": "https://finnhub.io/api/news?id=51347be87f89806a9331772ef84322ca498b19554d6d04c6e9f0864dd5d05b81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, which would be a potential fifth U.S. aesthetic indication. See our latest analysis for AbbVie. Alongside Allergan Aesthetics' Botox update and several recent approvals and guidance changes, AbbVie’s share price has moved to $247.97, with a 90 day share price return of 19.3% and a 1 year total...",
                "category": "company",
                "datetime": 1786482692,
                "headline": "AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?"
              },
              {
                "id": 141200621,
                "url": "https://finnhub.io/api/news?id=a08e7c7fa18be82606ea2feeb7ddeeada1626fe5e95e301c926252196ccedab8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.",
                "category": "company",
                "datetime": 1786481221,
                "headline": "AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 141189360,
                "url": "https://finnhub.io/api/news?id=f5932c9df04bd778e326a6ee5cebd833aba4d5b273c91902ce74816c1abdff6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Both of these stocks pay more than double the S&P 500 average of 1.1%.",
                "category": "company",
                "datetime": 1786468523,
                "headline": "Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?"
              },
              {
                "id": 141200526,
                "url": "https://finnhub.io/api/news?id=bb45ea9039c763833121ecfb68e434d16b3cf6fb8431480eca4c3f9568d605b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.",
                "category": "company",
                "datetime": 1786467240,
                "headline": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?"
              },
              {
                "id": 141200624,
                "url": "https://finnhub.io/api/news?id=36b93b198d828126826d33226504fa9d1104c2738ade7d2bb2d617000b8f436b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.",
                "category": "company",
                "datetime": 1786460414,
                "headline": "Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run"
              },
              {
                "id": 141188929,
                "url": "https://finnhub.io/api/news?id=054e1ed058edf4927c19ffb2c9283479609da027175841f5bcaabb478837c7e6",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "BNP Paribas  analyst Navann Ty   maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.",
                "category": "company",
                "datetime": 1786456534,
                "headline": "BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247"
              },
              {
                "id": 141200625,
                "url": "https://finnhub.io/api/news?id=a4f64e1367b0eeac052bdbb21dc48e23a1ab4e3feac3e16bc11a981beb1d3c2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges® (APP), its customer portfolio loyalty program, designed to better support the way today's aesthetics practices operate and grow. Shaped by customer feedback and market momentum, the program now introduces simpler savings, greater benefits transparency and expanded opportunities for practice growth, making it easier for customers to understand, access and maximize the value of their partnership with Al",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices"
              },
              {
                "id": 141200626,
                "url": "https://finnhub.io/api/news?id=49ac0507a45d1cb7207a32be4124e84155f52820dbe80fd6ed5d4efd0ede2563",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The pharmaceutical company hopes that another big-time acquisition will pay off.",
                "category": "company",
                "datetime": 1786446300,
                "headline": "AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141176631,
                "url": "https://finnhub.io/api/news?id=ca413707af7b6ebc1e4b5a8d925fc732324d990c17033e1fcd8bfdcb0a5c22ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]",
                "category": "company",
                "datetime": 1786381180,
                "headline": "AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141175296,
                "url": "https://finnhub.io/api/news?id=f343afcf599cec5059f6e3384f6e1fcfe83b4c90004ff60e199ddf20e99103ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "The stock is up just 8% this year and could prove to be an undervalued buy.",
                "category": "company",
                "datetime": 1786370641,
                "headline": "Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?"
              },
              {
                "id": 141174297,
                "url": "https://finnhub.io/api/news?id=69abc7bda0fef2cc41514d6b8a86bc01b40e4cb7b2b108f5ac878016d42a3aad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.",
                "category": "company",
                "datetime": 1786369539,
                "headline": "We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks."
              },
              {
                "id": 141176420,
                "url": "https://finnhub.io/api/news?id=c051b59f5a73b56e38d6aba01c778ec561b3bfd020bd5ce34cb5a2533cb10b81",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Evercore ISI Group  analyst Gavin Clark-Gartner   maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $246 to $260.",
                "category": "company",
                "datetime": 1786363337,
                "headline": "Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $260"
              },
              {
                "id": 141173839,
                "url": "https://finnhub.io/api/news?id=cdede5a86a1a9c715bcc2916ec012ef4f51f2e1958b7fa818b04daf0ff357e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.",
                "category": "company",
                "datetime": 1786363255,
                "headline": "3 Beaten-Down Healthcare Stocks to Buy in August"
              },
              {
                "id": 141174738,
                "url": "https://finnhub.io/api/news?id=79f38d590e34e831d31db42477bd1fdbd5b0b46115fb301503409749e238a15b",
                "image": "",
                "source": "Benzinga",
                "related": "ABBV",
                "summary": "Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share",
                "category": "company",
                "datetime": 1786346565,
                "headline": "Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate"
              },
              {
                "id": 141170024,
                "url": "https://finnhub.io/api/news?id=d0da7ae1c82aa7f3246b7500985fb1b061b1cb20ab34f3c7b72861cac2bd7407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "ABBV",
                "summary": "AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable gains in the neuroscience portfolio. CEO Robert Michael emphasized that “each [portfolio] delivered growth above 20%,” with SKYRIZI achieving market leadership in multiple countries. However, the quarter also saw persistent biosimilar pressure o",
                "category": "company",
                "datetime": 1786318402,
                "headline": "The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 132,
            "discarded_article_count": 115
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.1,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 3,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(10.6%→5.9%)；量縮(v10/v30=0.79)；跌縮量(近10日5日)；靠近20日高位；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 4910890,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": false,
              "avg_vol_10": 3885950,
              "avg_vol_20": 4274050,
              "avg_vol_30": 4910890,
              "range_pct_10": 0.05860599726666136,
              "range_pct_20": 0.09220998874507606,
              "range_pct_30": 0.10559530508883366,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7912924133914626,
              "dist_to_20d_high": 0.06813499644154783,
              "down_shrink_days": 5,
              "breakout_level_20d": 266.97,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5550057099352871
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.2966476404855696,
              "turnoverUsdM": 1278.8137852,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.ABBV",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 237.3528,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 4.6,
            "take_profit_price": 263.0735,
            "target_multiplier": 1.9,
            "technical_strength": 1.98,
            "take_profit_percent": 5.7
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.240939162699524,
          "stopLossPercent": 4.593295280971139,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 5.7136,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.3
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -92.58
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0738
    },
    "kdj": {
      "d": 45.32,
      "j": 2.43,
      "k": 31.02,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 44.45
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 34097260,
      "recentSlope": -1163264,
      "previousSlope": 1130540
    },
    "rsi": 38.86,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 266.97,
      "position": "SAR喺價上",
      "distancePct": 7.31,
      "previousTrend": "上升"
    },
    "ma50": 254.387,
    "macd": {
      "macd": 1.2200514138053222,
      "trend": "中性偏多",
      "signal": 2.4045666610163026,
      "histogram": -1.1845152472109803
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 257.4078,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.19,
      "score": 6,
      "avgVolume": 4320592,
      "currentVolume": 5140340
    },
    "derived": {
      "ma20": 257.578,
      "ma50": 254.387,
      "prevClose": 256.46,
      "avgVolume10": 4011624,
      "avgVolume20": 4320592,
      "changePercent": -2.99,
      "avgVolumeForScore": 4320592
    },
    "ma_cross": {
      "ma20": 257.578,
      "ma50": 254.387,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 257.5375,
      "prevMa50": 254.4784,
      "spreadPct": 1.25,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 245.7348,
      "upper": 269.4212,
      "position": "中間"
    },
    "rsi_short": 32.53,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.19
    }
  }
}

{
  "close": 248.78,
  "volume": 5140340,
  "changePercent": -2.99
}